Related Experiment Videos
A model for evaluating droperidol's effect on the median QTc interval
Yongfeng Zhang1, Ziping Luo, Paul F White
1New Drug Center at Amphastar Pharmaceuticals Inc., Rancho Cucamonga, California, USA.
Anesthesia and Analgesia
|April 24, 2004
Summary
Small doses of droperidol (antiemetic) are unlikely to cause dangerous heart rhythms. Mathematical modeling shows that typical antiemetic doses of droperidol do not significantly prolong the QT interval, suggesting safety in surgical patients.
Area of Science:
- Cardiology
- Pharmacology
- Medical Mathematics
Background:
- Droperidol, an antiemetic, faces controversy due to a "black box" warning linking it to serious arrhythmias.
- Concerns exist regarding the cardiac safety of even small droperidol doses in perioperative care.
Purpose of the Study:
- To evaluate the relationship between droperidol dosage and QT(c) interval prolongation using mathematical modeling.
- To assess the proarrhythmogenic potential of small-dose droperidol in surgical patients.
Main Methods:
- Mathematical modeling of QT interval data from a peer-reviewed study.
- Evaluation of various regression models (logarithm, linear, square-root, polynomial, exponent) to simulate QT(c) prolongation.
- Analysis of electrocardiographic QT interval data for droperidol doses ranging from 0.1-0.25 mg/kg i.v.
Main Results:
- The square-root model best simulated the experimentally measured QT(c) values.
- Estimated median QT(c) prolongation for droperidol 0.625-1.25 mg i.v. ranged from 9 ± 3 to 18 ± 3 ms.
- Calculated QT(c) prolongations were within clinically acceptable ranges across evaluated models.
Conclusions:
- Small-dose droperidol (≤1.25 mg) is unlikely to cause significant QT(c) prolongation.
- Mathematical modeling suggests that antiemetic doses of droperidol do not pose a substantial proarrhythmogenic risk in surgical patients.